|
Adenocarcinoma Of Esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prognostic value of Laurén classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction.
|
10340889 |
1999 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We examined the frequency, tumor characteristics, and prognostic impact of HER2 protein expression and gene amplification in patients with curatively resected esophageal adenocarcinoma (EAC).
|
22252257 |
2012 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to assess the dynamics of HER2 status in esophageal adenocarcinoma (EAC) in patients with resectable and recurrent disease, and to determine the associations of these changes with clinical outcome.
|
29928485 |
2018 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
There are conflicting data concerning the impact of HER2 overexpression on esophageal adenocarcinoma (EAC), as most studies do not differ between cancers of the esophagus/gastroesophageal junction and the stomach.
|
30621632 |
2019 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
This retrospective multicenter study included all consecutive patients with HER2-positive advanced gastro-esophageal adenocarcinoma treated with FOLFIRI plus trastuzumab between 2012 and 2015.
|
29090377 |
2018 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
ERBB2 was the most frequently amplified proto-oncogene among 25 esophageal adenocarcinoma tumors tested (greater than 10-fold amplification in 3 of 25 (12%) tumors tested).
|
15511476 |
2004 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this in vitro report we demonstrate the applicability of antibody-based NIR-tPDT in esophageal adenocarcinoma (EAC), using the phototoxic compounds cetuximab-IRDye700DX and trastuzumab-IRDye700DX, targeting respectively epidermal growth factor receptor 1 (EGFR) and 2 (HER2).
|
28415738 |
2017 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Testing of the HER2 status is crucial to ensure selection of the correct patient who may benefit from target therapy for esophageal adenocarcinoma.
|
29600365 |
2018 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Recent studies have demonstrated that HER2 and MET receptor tyrosine kinases are co-overexpressed in a subset esophageal adenocarcinoma (EAC).
|
31772236 |
2019 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Her2-Targeted Therapy Induces Autophagy in Esophageal Adenocarcinoma Cells.
|
30297650 |
2018 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, a functionally important regulation of Gli-1 by ErbB2-PI3K-mTORC signaling as well as a Gli-1-dependent regulation of Ihh in the ErbB2 amplified esophageal adenocarcinoma cell line OE19 was observed.
|
25435423 |
2015 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.
|
21267790 |
2011 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Magnetic Resonance Imaging (MRI) of Intratumoral Voxel Heterogeneity as a Potential Response Biomarker: Assessment in a HER2+ Esophageal Adenocarcinoma Xenograft Following Trastuzumab and/or Cisplatin Therapy.
|
28456115 |
2017 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells.
|
29223420 |
2018 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Promising markers that emerged for the prediction of overall survival in esophageal squamous cell cancer included VEGF (18 eligible studies, n=1476, HR=1.85, 95% CI, 1.55-2.21), cyclin D1 (12 eligible studies, n=1476, HR=1.82, 95% CI, 1.50-2.20), Ki-67 (3 eligible studies, n=308, HR=1.11, 95% CI, 0.70-1.78) and squamous cell carcinoma antigen (5 eligible studies, n=700, HR=1.28, 95% CI, 0.97-1.69); prognostic markers for esophageal adenocarcinoma included COX-2 (2 eligible studies, n=235, HR=3.06, 95% CI, 2.01-4.65) and HER-2 (3 eligible studies, n=291, HR=2.15, 95% CI, 1.39-3.33); prognostic markers for uncategorized ECs included p21 (9 eligible studies, n=858, HR=1.27, 95% CI, 0.75-2.16), p53 (31 eligible studies, n=2851, HR=1.34, 95% CI, 1.21-1.48), CRP (8 eligible studies, n=1382, HR=2.65, 95% CI, 1.64-4.27) and hemoglobin (5 eligible studies, n=544, HR=0.91, 95% CI, 0.83-1.00).
|
24206575 |
2013 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
In esophageal adenocarcinoma (EAC), concordance and prognostic significance of human epidermal growth factor 2 (HER-2) protein overexpression and gene amplification are equivocal, which led us to reevaluate this by immunohistochemistry (IHC) and in situ hybridization.
|
23334118 |
2013 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We applied our approach to HER-2/neu quantitative gene expression analysis in 54 microdissected tumor and nonneoplastic archival samples from patients with Barrett's esophageal adenocarcinoma and showed that the results matched those obtained in parallel by fluorescence in situ hybridization and immunohistochemistry.
|
11159180 |
2001 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma.
|
22745369 |
2012 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee.
|
29439009 |
2018 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
To support the obtained results, the qRT-PCR levels of microRNAs and their expression (in situ hybridization) were tested in an adjunctive series of gastric and esophageal adenocarcinoma, including (IHC/CISH validated) HER2-negative and HER2-positive cases.
|
23618359 |
2013 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of 24 patients with actionable mutations, five were given genotype-matched drugs corresponding to actionable mutations: everolimus to PIK3CA mutation in parotid carcinosarcoma (partial response) and tracheal squamous cell carcinoma (stable disease; 21% reduction), sorafenib to PDGFRA mutation in auditory canal adenocarcinoma (partial response), sorafenib to BRAF mutation in microcytic adnexal carcinoma (progressive disease), and afatinib to ERBB2 mutation in esophageal adenocarcinoma (progressive disease).
|
27105424 |
2016 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery.
|
20865050 |
2010 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effects of PTEN knockdown on the response to trastuzumab on cell viability, HER2 downstream signaling, apoptosis, and cell cycle were evaluated in HER2-overexpressing NCI-N87 gastric adenocarcinoma and OE19 esophageal adenocarcinoma cell lines.
|
27517839 |
2017 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study.
|
31809243 |
2020 |
|
Adenocarcinoma Of Esophagus
|
0.100 |
Biomarker
|
disease |
BEFREE |
We generated lapatinib-resistant (LR) subclones from an initially lapatinib-sensitive ERBB2-amplified esophageal adenocarcinoma cell line, OE19.
|
25350844 |
2014 |